Merck KGaA, Pfizer get priority review for bladder cancer drug

FRANKFURT (Reuters) - German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek to widen the use of immunotherapy drug avelumab to include bladder cancer.